Latest Trials Latest NewsFAQ

GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

Phase 2

Terminated

Conditions: B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion

Interventions: Drug: Idelalisib
Drug: Rituximab

First Posted Date: 2014-01-24

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 102

Registration Number: NCT02044822

Locations: 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸
The University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸
Illinois Cancer Specialists, Niles, Illinois, United States

and more 53 locations

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection

Phase 3

Completed

Conditions: Chronic HCV Infection

Interventions: Drug: LDV/SOF

First Posted Date: 2013-12-27

Last Posted Date: 2020-03-05

Lead Sponsor: Gilead Sciences

Target Recruit Count: 384

Registration Number: NCT02021656

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection

Phase 3

Completed

Conditions: Chronic HCV Infection

Interventions: Drug: Sofosbuvir
Drug: RBV
Drug: PEG

First Posted Date: 2013-12-27

Last Posted Date: 2018-02-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 687

Registration Number: NCT02021643

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Phase 2

Recruiting

Conditions: Acquired Immune Deficiency Syndrome (AIDS)
HIV Infections

Interventions: Drug: ATV
Drug: Third Unboosted Drug
Drug: DRV
Drug: LPV/r
Drug: Cobicistat TOS
Drug: Cobicistat
Drug: F/TAF
Drug: BR
Drug: F/TAF TOS

First Posted Date: 2013-12-20

Last Posted Date: 2024-11-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 130

Registration Number: NCT02016924

Locations: 🇹🇭
Siriraj Hospital, Bangkok, Thailand
🇹🇭
Srinagarind Hospital, Khon Kaen, Thailand
🇹🇭
Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand

and more 31 locations

Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Phase 2

Completed

Conditions: Chronic HCV Infection

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2013-12-12

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 334

Registration Number: NCT02010255

Locations: 🇫🇷
Hospital Mondor \\ Service d'Hépatologie et de Gastroentérologie,, Créteil, France
🇦🇹
Medizinische Universitat Wien, Wien, Austria
🇩🇪
Universitätsklinikum RWTH Aachen, Aachen, Germany

and more 31 locations

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

Phase 1

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: Velpatasvir

First Posted Date: 2013-12-06

Last Posted Date: 2020-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 19

Registration Number: NCT02002767

Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Phase 2

Completed

Conditions: HCV Infection

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2013-11-19

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 100

Registration Number: NCT01987453

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

Phase 2

Completed

Conditions: Chronic HCV Infection

Interventions: Drug: LDV/SOF
Drug: GS-9669
Drug: RBV

First Posted Date: 2013-11-14

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 101

Registration Number: NCT01984294

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Phase 3

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Chlorambucil
Drug: Idelalisib
Drug: Obinutuzumab

First Posted Date: 2013-11-11

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 57

Registration Number: NCT01980875

Locations: 🇺🇸
Sansum Clinic, Santa Barbara, California, United States
🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇫🇷
Centre Hospitalier de Perpignan, Perpignan Cedex 9, France

and more 15 locations

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Idelalisib
Drug: Rituximab
Drug: Bendamustine
Drug: Placebo

First Posted Date: 2013-11-11

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 311

Registration Number: NCT01980888

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇨🇦
Cancercare Manitoba - Maccharles Unit, Winnipeg, Manitoba, Canada
🇺🇸
Franciscan Physician Network Oncology & Hematology, Indianapolis, Indiana, United States

and more 87 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy